323 related articles for article (PubMed ID: 29843663)
21. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration.
Vedula SS; Krzystolik MG
Cochrane Database Syst Rev; 2008 Apr; (2):CD005139. PubMed ID: 18425911
[TBL] [Abstract][Full Text] [Related]
22. Different Outcomes of Anti-VEGF Treatment for Neovascular AMD according to Neovascular Sutypes and Baseline Features: 2-Year Real-Life Clinical Outcomes.
Arrigo A; Saladino A; Aragona E; Mercuri S; Introini U; Bandello F; Parodi MB
Biomed Res Int; 2021; 2021():5516981. PubMed ID: 34124243
[TBL] [Abstract][Full Text] [Related]
23. Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study).
Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Pecheur FL; Munk MR; McAllister IL
Ophthalmology; 2020 Feb; 127(2):198-210. PubMed ID: 31619357
[TBL] [Abstract][Full Text] [Related]
24. Twelve-month outcomes of treatment using ranibizumab or aflibercept for neovascular age-related macular degeneration: a comparative study.
Kim JH; Lee DW; Chang YS; Kim JW; Kim CG
Graefes Arch Clin Exp Ophthalmol; 2016 Nov; 254(11):2101-2109. PubMed ID: 27230919
[TBL] [Abstract][Full Text] [Related]
25. Worth changing? Clinical effects of switching treatment in neovascular age-related macular degeneration from intravitreal ranibizumab and aflibercept to bevacizumab in a region in southern Sweden.
Bro T; Hägg S
Eur J Ophthalmol; 2021 Jan; 31(1):144-148. PubMed ID: 31642333
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis.
Schmid MK; Bachmann LM; Fäs L; Kessels AG; Job OM; Thiel MA
Br J Ophthalmol; 2015 Feb; 99(2):141-6. PubMed ID: 25271911
[TBL] [Abstract][Full Text] [Related]
27. Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice.
Maloney MH; Payne SR; Herrin J; Sangaralingham LR; Shah ND; Barkmeier AJ
Ophthalmology; 2021 Mar; 128(3):417-424. PubMed ID: 32781110
[TBL] [Abstract][Full Text] [Related]
28. Aflibercept in the treatment of neovascular age-related macular degeneration in previously treated patients.
Hall LB; Zebardast N; Huang JJ; Adelman RA
J Ocul Pharmacol Ther; 2014 May; 30(4):346-52. PubMed ID: 24552305
[TBL] [Abstract][Full Text] [Related]
29. Effect of Anti-VEGF Therapy on the Disease Progression of Neovascular Age-Related Macular Degeneration: A Systematic Review and Model-Based Meta-Analysis.
Luu KT; Seal J; Green M; Winskill C; Attar M
J Clin Pharmacol; 2022 May; 62(5):594-608. PubMed ID: 34783362
[TBL] [Abstract][Full Text] [Related]
30. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
Shalchi Z; Mahroo O; Bunce C; Mitry D
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD009510. PubMed ID: 32633861
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
Woo SJ; Veith M; Hamouz J; Ernest J; Zalewski D; Studnicka J; Vajas A; Papp A; Gabor V; Luu J; Matuskova V; Yoon YH; Pregun T; Kim T; Shin D; Bressler NM
JAMA Ophthalmol; 2021 Jan; 139(1):68-76. PubMed ID: 33211076
[TBL] [Abstract][Full Text] [Related]
32. Comparative Efficacy of Brolucizumab in the Treatment of Neovascular Age-Related Macular Degeneration: A Systematic Literature Review and Network Meta-Analysis.
Finger RP; Dennis N; Freitas R; Quenéchdu A; Clemens A; Karcher H; Souied EH
Adv Ther; 2022 Aug; 39(8):3425-3448. PubMed ID: 35678996
[TBL] [Abstract][Full Text] [Related]
33. Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti-VEGF Drug Type for 1 Year in the IRIS Registry.
Rao P; Lum F; Wood K; Salman C; Burugapalli B; Hall R; Singh S; Parke DW; Williams GA
Ophthalmology; 2018 Apr; 125(4):522-528. PubMed ID: 29146306
[TBL] [Abstract][Full Text] [Related]
34. PREDICTORS OF ONE-YEAR VISUAL OUTCOMES AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Kodjikian L; Decullier E; Souied EH; Roux A; Aulagner G; Huot L;
Retina; 2018 Aug; 38(8):1492-1499. PubMed ID: 28654629
[TBL] [Abstract][Full Text] [Related]
35. Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT.
Hykin P; Prevost AT; Sivaprasad S; Vasconcelos JC; Murphy C; Kelly J; Ramu J; Alshreef A; Flight L; Pennington R; Hounsome B; Lever E; Metry A; Poku E; Yang Y; Harding SP; Lotery A; Chakravarthy U; Brazier J
Health Technol Assess; 2021 Jun; 25(38):1-196. PubMed ID: 34132192
[TBL] [Abstract][Full Text] [Related]
36. Neovascular age-related macular degeneration treated with ranibizumab or aflibercept in the same large clinical setting: visual outcome and number of injections.
Rasmussen A; Sander B; Larsen M; Brandi S; Fuchs J; Hansen LH; Lund-Andersen H
Acta Ophthalmol; 2017 Mar; 95(2):128-132. PubMed ID: 27535819
[TBL] [Abstract][Full Text] [Related]
37. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease.
Tolentino M
Surv Ophthalmol; 2011; 56(2):95-113. PubMed ID: 21335144
[TBL] [Abstract][Full Text] [Related]
38. Anti-vascular endothelial growth factor for diabetic macular oedema.
Virgili G; Parravano M; Menchini F; Evans JR
Cochrane Database Syst Rev; 2014 Oct; (10):CD007419. PubMed ID: 25342124
[TBL] [Abstract][Full Text] [Related]
39. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.
Carrasco J; Pietsch GA; Nicolas MP; Koerber C; Bennison C; Yoon J
Adv Ther; 2020 Jan; 37(1):300-315. PubMed ID: 31728825
[TBL] [Abstract][Full Text] [Related]
40. Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: Two-Year Results.
; ; Martin DF; Maguire MG; Fine SL; Ying GS; Jaffe GJ; Grunwald JE; Toth C; Redford M; Ferris FL
Ophthalmology; 2020 Apr; 127(4S):S135-S145. PubMed ID: 32200813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]